Chronic myelogenous leukemia: Clinical practice guidelines in oncology

Susan O'Brien, Ellin Berman, Kapil Bhalla, Edward A. Copelan, Marcel P. Devetten, Peter D. Emanuel, Harry P. Erba, Peter L. Greenberg, Joseph O. Moore, Donna Przepiorka, Jerald P. Radich, Russell J. Schilder, Paul Shami, B. Douglas Smith, David S. Snyder, Robert J. Soiffer, Martin S. Tallman, Moshe Talpaz, Meir Wetzler

Research output: Contribution to journalReview articlepeer-review

Abstract

Chronic myelogenous leukemia (CML) accounts for 15% of adult leukemias. In 2005, an estimated 4,600 cases will be diagnosed, and 850 patients will die of the disease. The median age of disease onset is 53 years; however, CML occurs in all age groups, with an increasing proportion of younger patients in more recent series. ML progresses from a chronic phase to a rapidly fatal blastic phase, generally over 3 to 5 years. The blast phase is often preceded by a transition period, called the accelerated phase, which is marked by the acquisition of new cytogenetic abnormalities in 50% to 80% of patients. Several definitions of the accelerated phase of the disease are summarized.

Original languageEnglish (US)
Pages (from-to)732-755
Number of pages24
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume3
Issue number6
DOIs
StatePublished - Nov 2005

Keywords

  • Acute lymphocytic leukemia
  • Allogeneic transplantation
  • Chronic myelogenous leukemia
  • Cytarabine
  • Hematopoietic stem cell transplant
  • Imatinib mesylate
  • Interferon
  • NCCN Clinical Practice Guidelines

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Chronic myelogenous leukemia: Clinical practice guidelines in oncology'. Together they form a unique fingerprint.

Cite this